Achieve Life Sciences (ACHV) Restructuring Costs (2016)
Achieve Life Sciences (ACHV) recorded quarterly Restructuring Costs of -$431000.0 in Q3 2016, down 131.35% on a QoQ basis from $1.4 million in Q2 2016.
Achieve Life Sciences (ACHV) Restructuring Costs (2016) Analysis & Trends
Achieve Life Sciences has disclosed Restructuring Costs across 1 years of filings, most recently posting -$431000.0 for Q3 2016.
- Quarterly Restructuring Costs changed N/A year-over-year to -$431000.0 in Q3 2016, while the trailing twelve-month figure through Dec 2016 was $1.4 million (changed N/A YoY) and the FY2016 annual result came in at $1.4 million, changed N/A from the prior year.
- Restructuring Costs eased to -$431000.0 in Q3 2016, from $1.4 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $1.4 million in Q2 2016 and troughed at -$431000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | -431,000.00 |
| Jun 30, 2016 | 1.38 Mn |
| Mar 31, 2016 | 431,000.00 |